Kidney Cancer Coalition & KCAN: Stronger Together

Kidney Cancer Coalition and KCAN have joined forces to accelerate life-saving research and clinical trials for kidney cancer.

The union of these two complementary charitable organizations represents a promising step for the kidney cancer community.

Together, we’ll be known as KidneyCAN—carrying that name forward while embracing the “CAN” legacy to reinforce our driven and optimistic vision for our role in the fight against this deadly disease.

Battling what is among the most prevalent forms of cancer among men (#6) and women (#10) in the U.S.*—yet still among the most under-funded and under-recognized cancers— patients, caregivers, advocates, and scientists are in dire need of greater awareness, funding, and action. That is our focus.

As one, we bring proven effectiveness at raising money for research—from grassroots efforts, to private contributions and corporate grants, up through substantial federal funding. Our impact in just four combined years of existence includes:

Spearheading efforts to initiate a $45 million Congressional grant program for research;

Raising over $1 million through local efforts and events including our “Rock the Cure” fundraisers, with over $625,000 already put to work in research labs and studies;

Leading the first-ever grassroots-funded clinical trial for kidney cancer; and

Earning a reputation for being extremely efficient at deploying capital directly to clinical and scientific endeavors in pursuit of breakthroughs.

Our founders—Brenda and Ralph Knapp, who started KC Coalition in 2016, and Bryan Lewis, who formed KCAN in 2017—recognized the potential benefits of pooling their strengths and resources. These three devoted leaders have personal experiences with kidney cancer, as patients, caregivers, and advocates. Their commitment to the cause is profound.

Brenda, Ralph, and Bryan remain confident that we “CAN” find a cure in our lifetime, despite the historical lack of funding—particularly compared to other forms of cancer—which continues to leave a severe shortage of trials resulting in roughly 15,000 deaths in the U.S. each year.*

COMING SOON

KIDNEY CANCER RESEARCH SUMMIT

#KCRS2019

SEPTEMBER 2019

PHILADELPHIA, PA

Bryan Lewis, President & Co-Founder

Co-Chairs Drs. Hans Hammers & Tony Choueiri

Brenda Knapp, Treasurer & Co-Founder

We are proud to host the 1st annual Kidney Cancer Research Summit bringing together renowned scientists, young investigators, industry and research advocates.

We had a successful advocacy day on the Hill March 12th

Thank you to all who let your voice be heard

In the News

July 16, 2018 / News Page

Newly diagnosed metastatic renal cell carcinoma

Daniel George, MD; Toni Choueiri, MD; Walter Stadler, MD; and Richard W. Joseph, MD, discuss data from the CABOSUN trial and the expanded FDA approval for cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma.
Read More
July 16, 2018 / News Page

Cancer patient saved by ‘seek and destroy’ cells

The first NHS cancer patient to benefit from a breakthrough procedure that primes the body’s immune system to ‘seek and destroy’ tumour cells has stunned doctors with his recovery after being given just weeks to live.
Read More
July 5, 2018 / News Page

American Cancer Society Current Grants

American Cancer Society Current Grants by Cancer Type Current as of March 1, 2018 Cancer Type Number of Grants involving...
Read More
July 3, 2018 / News Page

Dr Choueiri discusses checkpoint inhibitors in RCC

CLICK HERE TO VIEW THE VIDEO
Read More
June 28, 2018 / News Page

The PIVOT-02 Trial: NKTR-214 With Nivolumab

Adi Diab, MD, discusses the synergistic mechanisms of NKTR-214 and nivolumab and the promising results of the phase I/II PIVOT-02 trial evaluating the use of NKTR-214 combined with nivolumab in multiple solid tumor types.
Read More
June 26, 2018 / News Page

Heading Toward Personalized Management of Advanced Kidney Cancer

The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.
Read More
Donate Now!

Since our inception in 2016, we have proudly given over $625,000 to Kidney Cancer Research!

WE ARE A GRASSROOTS ORGANIZATION DEDICATED TO MAKING A DIFFERENCE IN THE KIDNEY CANCER COMMUNITY

Funded major projects to date include:

  • RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.

  • Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.

 Our primary sources of support are donations from the general public and fundraising.  

Our mission is to abolish Kidney Cancer as a threat to the life and health of patients through advocacy and accelerating research by  offering direct financial support for clinical and laboratory researchers with promising ideas.

LEARN MORE

Kidney Cancer strikes 63,340/year

14,970/year die from the disease

We want to help change those statistics!